SEC Comment Letter 0000000000-23-011204 to SpringWorks Therapeutics, Inc. (SWTX) (CIK 0001773427)
SpringWorks Therapeutics, Inc. (SWTX) (CIK 0001773427)
Date: Oct. 13, 2023 · CIK: 0001773427 · Accession: 0000000000-23-011204
AI Filing Summary & Sentiment
File numbers found in text: 001-39044
Letter
United States securities and exchange commission logo October 13, 2023 Saqib Islam Chief Executive Officer SpringWorks Therapeutics, Inc. 100 Washington Blvd Stamford, CT 06902 Re:SpringWorks Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed February 28, 2023 File No. 001-39044 Dear Saqib Islam: We have limited our review of your filing to the financial statements and related disclosures and have the following comments. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Notes to the Consolidated Financial Statements Management's Discussion and Analysis Results of Operations Research and development expenses, page 107 1.You disclose on page 7 that you have multiple product candidates with different indications and on page 105 you state that you track external research and development expenses on a program-by-program basis. Please provide us, and confirm you will disclosure in future filings, a table which disaggregates external research and development expense by program. Include other line items in the table, as necessary, including any amounts that are not allocated, with the total reconciling to the amount on the Income Statement. 10. License and Collaboration Agreements, page 135 2.For your EGFR and TEAD license agreements, please provide us proposed disclosure which will be disclosed in future filings regarding the specific terms of
FirstName LastNameSaqib Islam Comapany NameSpringWorks Therapeutics, Inc. October 13, 2023 Page 2 FirstName LastName Saqib Islam SpringWorks Therapeutics, Inc. October 13, 2023 Page 2 each agreement, including, as applicable, the amount of the upfront payment, milestone payments disaggregated into the nature of each milestone, and the royalty rate or range that does not exceed a ten point range. In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Mary Mast at 202-551-3613 or Daniel Gordon at 202-551-3486 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
October 13, 2023
Saqib Islam
Chief Executive Officer
SpringWorks Therapeutics, Inc.
100 Washington Blvd
Stamford, CT 06902
Re:SpringWorks Therapeutics, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2022
Filed February 28, 2023
File No. 001-39044
Dear Saqib Islam:
We have limited our review of your filing to the financial statements and related
disclosures and have the following comments.
Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments.
Notes to the Consolidated Financial Statements
Management's Discussion and Analysis
Results of Operations
Research and development expenses, page 107
1.You disclose on page 7 that you have multiple product candidates with different
indications and on page 105 you state that you track external research and development
expenses on a program-by-program basis. Please provide us, and confirm you will
disclosure in future filings, a table which disaggregates external research and development
expense by program. Include other line items in the table, as necessary, including any
amounts that are not allocated, with the total reconciling to the amount on the Income
Statement.
10. License and Collaboration Agreements, page 135
2.For your EGFR and TEAD license agreements, please provide us proposed disclosure
which will be disclosed in future filings regarding the specific terms of
FirstName LastNameSaqib Islam
Comapany NameSpringWorks Therapeutics, Inc.
October 13, 2023 Page 2
FirstName LastName
Saqib Islam
SpringWorks Therapeutics, Inc.
October 13, 2023
Page 2
each agreement, including, as applicable, the amount of the upfront payment, milestone
payments disaggregated into the nature of each milestone, and the royalty rate or range
that does not exceed a ten point range.
In closing, we remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
Please contact Mary Mast at 202-551-3613 or Daniel Gordon at 202-551-3486 with any
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences